Endothelial cell binding coatings for rapid encapsulation of bioerodable stents

• US 7,637,941 B1
• Filed: 05/11/2005
• Issued: 12/29/2009
• Est. Priority Date: 05/11/2005
• Status: Expired due to Fees

• Current Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Moberg Abreu, Anne, Hossainy, Syed Faiyaz Ahmed, Manicka, Yatheendhar, Claude, Charles
• Primary Examiner(s): GHERBI, SUZETTE JAIME J
• Application Number:
  US11/128,099
• Time in Patent Office: 1,693 Days
• Field of Search: 623 14- 149, 523/113, 422/33
• US Class Current: 623/1.42
• CPC Class Codes: A61L 2300/40 characterised by a specific therapeutic activity or mode of action
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 71/02 Polyalkylene oxides

Abstract

Bioerodable devices such as stents containing one or more endothelial cell binding agents are provided.

Claims

1. A bioerodable device comprising an endothelial cell (EDC) binding agent, wherein the EDC binding agent is selected from the group consisting of collagen type 1, the active fragment of osteopontin, scFV A5, junction membrane protein vascular endothelial (VE)-cadherin, RGD peptide, RGD peptide mimetics, and combinations thereof, and

wherein the EDC binding agent is chemically linked to the bioerodable device.

2. The bioerodable device of claim 1, wherein the EDC binding agent is coated onto the bioerodable device in the form of a coating.

3. The bioerodable device of claim 2, wherein the coating further comprises a polymer.

4. The bioerodable device of claim 3, wherein the polymer is a biodegradable polymer.

5. The bioerodable device of claim 3, wherein the polymer comprises methacrylate or acrylate monomers.

6. The bioerodable device of claim 1, wherein the EDC binding agent is selected from the group consisting of collagen type 1, the active fragment of osteopontin, scFV A5, and combinations thereof.

7. The bioerodable device of claim 1, further comprising a biobeneficial material.

8. The bioerodable device of claim 1, further comprising a bioactive agent.

9. The bioerodable device of claim 8, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, prodrugs thereof, co-drugs thereof, and a combination thereof.

10. A method of treating a disorder in a patient comprising implanting in the patient the device of claim 1, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

11. A bioerodable stent comprising an endothelial cell (EDC) binding agent, wherein the EDC binding agent is selected from the group consisting of collagen type 1, the active fragment of osteopontin, scFV A5, junction membrane protein vascular endothelial (VE)-cadherin, RGD peptide, RGD peptide mimetics, and combinations thereof, and

wherein the EDC binding agent is chemically linked to the bioerodable stent.

12. The stent of claim 11, wherein the EDC binding agent is coated onto the bioerodable device in the form of a coating.

13. The stent of claim 12, wherein the coating further comprises a polymer.

14. The stent of claim 13, wherein the polymer is a biodegradable polymer.

15. The stent of claim 13, wherein the polymer is a biodegradable polymer.

16. The stent of claim 11, wherein the EDC binding agent is selected from the group consisting of collagen type 1, the active fragment of osteopontin, scFV A5, and combinations thereof.

17. The stent of claim 11, further comprising a biobeneficial material.

18. The stent of claim 11, further comprising a bioactive agent.

19. The bioerodable device of claim 18, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, ABT-578, pimecrolimus, imatinib mesylate, midostaurin, clobetasol, prodrugs thereof, co-drugs thereof, and a combination thereof.

20. A method of treating a disorder in a patient comprising implanting in the patient the stent of claim 11, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.